New hope for stomach cancer patients who failed first treatment
Disease control
Recruiting now
This study tests a combination of three drugs (SHR-1701, rivoceranib, and possibly SHR-2554) in 40 adults with advanced stomach or gastroesophageal junction cancer that worsened after or could not tolerate first-line immunotherapy. The goal is to see if the new combo can shrink t…
Phase: PHASE2 • Sponsor: Jingdong Zhang • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC